ICR Divisions
Collections in this community
Recent submissions
-
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
(AMER ASSOC ADVANCEMENT SCIENCE, 2015-11-11)Acquired ESR1 mutations are a major mechanism of resistance to aromatase inhibitors (AIs). We developed ultra high-sensitivity multiplex digital polymerase chain reaction assays for ESR1 mutations in circulating tumor DNA ... -
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
(NATURE PUBLISHING GROUP, 2013-12-01)Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological and genetic levels. Tumor invasiveness (T) and grade (G) are the main factors associated with outcome and determine patient management. A ... -
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
(AMER SOC CLINICAL ONCOLOGY, 2018-04-01)Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis ... -
De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.
(SPRINGER, 2022-07-27)Purpose of Review: De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened ... -
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer.
(Bioscientifica, 2022-08-01)Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the ... -
Immune reconstitution in children following chemotherapy for acute leukemia.
(Wiley, 2020-07-01)Although survival rates for pediatric acute lymphoblastic leukemia are now excellent, this is at the expense of prolonged chemotherapy regimens. We report the long-term immune effects in children treated according to the ... -
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
(ELSEVIER SCI LTD, 2022-07-01)BACKGROUND: Adenocarcinoma with more than 50% extracellular mucin is a relatively rare histological subtype of gastrointestinal adenocarcinomas. The clinical impact of extracellular mucin in oesophageal adenocarcinoma ... -
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
(American Society of Clinical Oncology (ASCO), 2022-05-23)PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the ... -
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma.
(American Association for Cancer Research (AACR), 2022-05-26)PURPOSE: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. EXPERIMENTAL ... -
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma
(MDPI AG, 2022-08-04)<jats:p>Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines ... -
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
(FUTURE MEDICINE LTD, 2022-05-24)Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell ... -
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
(Elsevier BV, 2022-08-01)BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common type of breast cancer after invasive breast cancer of no special type (NST), representing up to 15% of all breast cancers. DESIGN: Latest data on ... -
Breast cancer and common malignancies in older adults
(Institute of Cancer Research (University Of London), 2022-08-08)Cancer is increasingly a diseases of older adults. However, they are heterogeneous and life expectancy and tolerance to stressors may vary greatly within this age group. Comorbidities, functional impairments, malnutrition, ... -
Magnetic resonance guided radiotherapy for the treatment of bladder and pancreatic cancer
(Institute of Cancer Research (University Of London), 2022-08-05)Magnetic resonance guided radiotherapy (MRgRT) has many postulated benefits over conventional radiotherapy treatment techniques. Its superior soft tissue definition, lack of imaging related ionising radiation and the ...
RSS 1.0